BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 16229924)

  • 21. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
    Verspohl EJ
    Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
    [No Abstract]   [Full Text] [Related]  

  • 23. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New drugs for the treatment of obesity].
    Mustajoki P
    Duodecim; 1999; 115(20):2191, 2193-4. PubMed ID: 11973921
    [No Abstract]   [Full Text] [Related]  

  • 25. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
    Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
    Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
    Toubro S
    Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
    [No Abstract]   [Full Text] [Related]  

  • 27. Weight loss medications--where do they fit in?
    Dixon JB
    Aust Fam Physician; 2006 Aug; 35(8):576-9. PubMed ID: 16894428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity, cardiovascular risk and pharmacotherapy.
    Ruilope LM; Garcia-Robles R; Moreno B
    Blood Press; 2002; 11(5):260-2. PubMed ID: 12458647
    [No Abstract]   [Full Text] [Related]  

  • 29. Combining behavioral and pharmacological treatments for obesity.
    Phelan S; Wadden TA
    Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic agents for the treatment of obesity.
    Mathys M
    Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging strategies for weight management. Summary.
    Hansen BC
    Postgrad Med; 2001 Jun; 109(6 Suppl):40-4. PubMed ID: 19667567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
    Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
    Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Kim C; Lau J
    Arch Intern Med; 2004 Jul; 164(13):1395-404. PubMed ID: 15249348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New pharmacological directions for the treatment of overweight and obesity.
    Van Gaal LF; Peiffer FW; De Leeuw IH
    Acta Clin Belg; 1999 Jun; 54(3):141-6. PubMed ID: 10443041
    [No Abstract]   [Full Text] [Related]  

  • 37. Incorrect use of orlistat and sibutramine in clinical practice.
    Dahlin A; Beermann B
    Eur J Clin Pharmacol; 2007 Feb; 63(2):205-9. PubMed ID: 17205321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring synergies in the treatment of obesity.
    Wadden TA
    Postgrad Med; 2001 Jun; 109(6 Suppl):29-33. PubMed ID: 19667565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.